Literature DB >> 19544100

[High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children].

S Agudo1, T Alarcón, L Cibrelus, P Urruzuno, M J Martínez, M López-Brea.   

Abstract

OBJECTIVE: To determine the primary and secondary resistance to several antimicrobial agents in Spanish Helicobacter pylori clinical isolates obtained from paediatric patients from January 2002 to June 2006.
METHODS: Samples were collected from gastric biopsies of symptomatic paediatric patients and H. pylori cultured according to standard microbiological procedures. Resistance was determined by E-test. Strains were considered resistant if minimal inhibitory concentration (MIC) > or = 2 mg/l for amoxycillin, > or = 4 mg/l for tetracycline, > or = 8 mg/l for metronidazole, > or = 1 mg/l for clarithromycin, MIC > or = 4 mg/l for ciprofloxacin, MIC > or = 32 mg/l for rifampicin and intermediate if MIC = 0.5 mg/l for clarithromycin, and MIC = 2 mg/l for ciprofloxacin.
RESULTS: A total of 101 patients were included: 38 males and 63 females (sex ratio M/F: 0.6). Average age was 10 years (range: 4-18 years). All strains were susceptible to amoxycillin, tetracycline and rifampicin, 35.7% were resistant to metronidazole, 54.6% to clarithromycin and 1.8% to ciprofloxacin. 2.0% were intermediate to clarithromycin and 1.8% to ciprofloxacin. Double resistance to metronidazole and clarithromycin rated at 17.2%. Thirty-five patients (34.7%) had a history of treatment failure, and were considered as secondary H. pylori. Primary resistance rates to metronidazole and clarithromycin were 32.8% and 49.2%, respectively, and secondary resistance rates were 41.2% and 70.6%, respectively.
CONCLUSIONS: Resistance to clarithromycin (56.6%) was higher than to metronidazole (35.7%) in the H. pylori strains studied. Clarithromycin resistance was very high even in strains from paediatric patients not previously treated for H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544100

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  11 in total

1.  In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.

Authors:  Ekaterina Gavrish; Binu Shrestha; Chao Chen; Ida Lister; E Jeffrey North; Lei Yang; Richard E Lee; Angel Han; Bronwyn Williams; David Charnuska; Ken Coleman; Kim Lewis; Michael D LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Antibiotic resistance of Helicobacter pylori in pediatric patients -- 10 years' experience.

Authors:  Iva Hojsak; Tea Kos; Jelena Dumančić; Zrinjka Mišak; Oleg Jadrešin; Alemka Jaklin Kekez; Amarela Lukić Grlić; Sanja Kolaček
Journal:  Eur J Pediatr       Date:  2012-03-20       Impact factor: 3.183

3.  Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran.

Authors:  Shohreh Farshad; Abdolvahab Alborzi; Aziz Japoni; Reza Ranjbar; Kazem Hosseini Asl; Parisa Badiee; Maneli Amin Shahidi; Marziyeh Hosseini
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

4.  Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism.

Authors:  S Agudo; G Pérez-Pérez; T Alarcón; M López-Brea
Journal:  Rev Esp Quimioter       Date:  2011-03       Impact factor: 1.553

5.  High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain.

Authors:  Sonia Agudo; Guillermo Pérez-Pérez; Teresa Alarcón; Manuel López-Brea
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

Review 6.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.

Authors:  Reza Ghotaslou; Hamed Ebrahimzadeh Leylabadlo; Yalda Mohammadzadeh Asl
Journal:  World J Methodol       Date:  2015-09-26

7.  Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children.

Authors:  Tita Butenko; Samo Jeverica; Rok Orel; Matjaž Homan
Journal:  Helicobacter       Date:  2017-06-27       Impact factor: 5.753

8.  Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates.

Authors:  Laure Brigitte Kouitcheu Mabeku; Bertrand Eyoum Bille; Cromwell Tepap Zemnou; Lionel Danny Tali Nguefack; Hubert Leundji
Journal:  BMC Infect Dis       Date:  2019-10-22       Impact factor: 3.090

9.  The Effects of Two Novel Copper-Based Formulations on Helicobacter pylori.

Authors:  Ilaria M Saracino; Cristina Zaccaro; Giovanna Lo Re; Dino Vaira; John Holton
Journal:  Antibiotics (Basel)       Date:  2013-05-21

10.  A Comparison between Hybrid and Concomitant Regimens for Helicobacter Pylori Eradication: A Randomized Clinical Trial.

Authors:  Saman Alhooei; Hafez Tirgar Fakheri; Vahid Hosseini; Iradj Maleki; Tarang Taghvaei; Seyed Mohammad Valizadeh; Zohreh Bari
Journal:  Middle East J Dig Dis       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.